For most individuals with hepatitis B, tenofovir alafenamide is generally considered the preferred medication, provided it is available.
This preference stems from its high efficacy and favorable profile in managing the hepatitis B virus (HBV). Tenofovir alafenamide is particularly effective in suppressing the hepatitis B virus, even in cases where the virus has developed resistance to other common antiviral agents.
Its broad-spectrum activity against various HBV strains makes it a reliable choice for long-term treatment. Specifically, tenofovir is known to be effective against HBV that has shown resistance to:
- Lamivudine
- Telbivudine
- Adefovir
- Entecavir
By effectively combating these resistant strains, tenofovir alafenamide helps ensure sustained viral suppression, which is crucial for preventing disease progression and liver damage in people living with chronic hepatitis B. Treatment decisions should always be made in consultation with a healthcare professional to determine the most appropriate therapy for individual circumstances.
